David Bethune, chairman and CEO of Zila, said: “India is obviously a major market that represents an excellent opportunity for ViziLite Plus. Through our relationship with Getwell, we plan to aggressively introduce our product all over the country.
“We are working closely with Getwell to gain the necessary regulatory approvals required by the Indian government in order to begin selling ViziLite Plus, which we expect to take approximately three months.”
Suresh Pathak, CEO and director of Getwell Life Sciences, said: “Oral cancer is the most common cancer in India, accounting for nearly 12% of all cancers detected and 50% to 70% of cancer-related deaths. The widespread practice of chewing various forms of tobacco and betel nut and smoking tobacco are the major causes of oral cancer.”